Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans reduced its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,928 shares of the specialty pharmaceutical company’s stock after selling 369 shares during the period. Thrivent Financial for Lutherans owned 0.08% of Collegium Pharmaceutical worth $714,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in COLL. Principal Financial Group Inc. grew its position in Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after buying an additional 64,958 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock worth $29,974,000 after purchasing an additional 5,464 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Collegium Pharmaceutical by 4.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company’s stock valued at $14,741,000 after purchasing an additional 16,655 shares during the last quarter. Royce & Associates LP lifted its holdings in shares of Collegium Pharmaceutical by 11.0% during the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company’s stock valued at $9,728,000 after purchasing an additional 33,674 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Collegium Pharmaceutical by 173.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock valued at $10,711,000 after purchasing an additional 175,892 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on COLL. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday, January 10th. Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Trading Up 2.1 %

COLL stock opened at $30.00 on Thursday. The business has a fifty day moving average of $30.16 and a 200-day moving average of $32.28. The company has a market cap of $944.58 million, a P/E ratio of 12.93 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. As a group, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Colleen Tupper sold 1,949 shares of the business’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the sale, the chief financial officer now directly owns 177,195 shares of the company’s stock, valued at approximately $5,315,850. The trade was a 1.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock valued at $3,243,594 in the last three months. 3.98% of the stock is currently owned by corporate insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.